Renal Effects of Erythropoietin in Humans (EPO 2012)

November 4, 2013 updated by: Niels Jacob Aachmann-Andersen, University of Copenhagen

Erythropoietin (EPO) is a glycoprotein produced mainly in the kidney. After its release to the bloodstream EPO binds to its receptor predominantly located within the bone marrow where erythropoiesis is stimulated. Recently, we have shown that recombinant human EPO (rHuEPO) down-regulates circulating levels of renin and aldosterone. Concomitant clearance studies revealed a decrease in proximal tubular reabsorption of sodium and water and a fall in glomerular filtration rate (GFR). These results for the first time demonstrate a link between EPO and renal function: By inhibiting proximal tubular reabsorption, which in turn results in rapid declines in GFR and renin/aldosterone levels, EPO may directly reduce the major oxygen consuming factor in the kidney. The expected result will be an increase of the oxygen tension in the environment of renal EPO producing cells, in this way initiating an appropriate signal for down-regulation of endogenous EPO synthesis when circulating levels of EPO are high.

The aim of this project is to test this hypothesis by investigating the renal effects of rHuEPO in humans. In a double-blinded manner healthy subjects will be tested with placebo, or low-dose rHuEPO for two weeks, or high-dose rHuEPO for three days. Accurate sodium balance studies will be conducted together with renal clearance studies for measurements of renal plasma flow (131I-Hippuran clearance with renal venous sampling), GFR (51Cr-EDTA clearance) and the segmentel tubular handling of sodium and water (lithium clearance).

EPO is the sole haematopoietic growth factor that is mainly produced in the kidneys and the project will provide new information about basic physiological issues regarding the association between renal function and the regulation of EPO synthesis.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The haematopoietic effect of EPO and rHuEPO has been known for five decades but still the exact mechanisms for regulation of EPO synthesis in the kidneys remain unclear. Recently, we confirmed our previous observation that rHuEPO in normal subjects produces arterial hypertension and a reduction in plasma volume. Moreover, the study delineated the time course of these changes: rHuEPO promptly, and before any changes in hematocrit, blood volumes and blood pressure can be detected, causes a down-regulation of the renin-aldosterone system, proximal tubular reabsorption and GFR.

The effect of rHuEPO on arterial blood pressure has been demonstrated to occur independent of its haematopoietic effect and subsequent effect on blood viscosity. Recently, we reported that also short-time administration of very high doses of rHuEPO (30,000 IU/day for three days) increases arterial blood pressure and the blood pressure response to exercise to a similar extent as prolonged, low-dose rHuEPO for three month. The exact mechanisms remains unclear, but may involve rHuEPO induced release of endothelin and inhibition of eNOS mediated production of NO.

The early rHuEPO induced reduction of renin and aldosterone was not caused by changes in plasma and blood volumes. A fall in intravascular volume normally leads to the opposite effect due to a decreased NaCl load to the macula densa and an increased sympathetic stimulation of the juxtaglomerular apparatus. The link between administration of rHuEPO and the renin-angiotensinaldosterone system is interesting because the production of endogenous EPO is regulated by this system. Administration of angiotensin II in humans stimulates EPO synthesis and, conversely, inhibitors of angiotensin converting enzyme and angiotensin II receptors decrease the plasma concentration of endogenous EPO. In patients with type-1 diabetes, an inherent high activity of basal renin-angiotensin system (in part governed by genetic factors) was associated with higher levels of EPO compared to patients with a low activity of basal renin-angiotensin system. Our results suggest that rHuEPO may activate an opposite pathway so as to down-regulate the activity of the renin-angiotensin-aldosterone system independent of changes in red blood cell mass, blood volumes and blood pressure.

Our renal clearance data suggest that the rHuEPO-induced inhibition of the renin-aldosterone system is associated with a reduction of absolute proximal tubular reabsorption of fluid and a fall in GFR. Changes in end-proximal delivery of tubular fluid to the macula densa produce inverse changes in renin release and thus the suppression of plasma renin levels may be secondary to direct effects of rHuEPO on proximal tubular reabsorption. In addition, a decrease in proximal tubular reabsorption activates the tubuloglomerular feedback mechanism causing a parallel decrease in GFR. The exact molecular mechanisms for rHuEPO's effect on the proximal tubule remain unknown but may involve inhanced release of renal endothelin-1 which in low doses attenuates sodium reabsorption in the proximal tubule. Tubular reabsorption of sodium is the main oxygen consuming process in the kidney and around 70 % of the filtered load is reabsorbed in the proximal tubule. By inhibiting proximal tubular reabsorption, which in turn results in rapid declines in GFR and renin/aldosterone levels, rHuEPO may directly reduce the major oxygen consuming factor in the kidney, reduce the filtered load, and decrease angiotensin II and aldosterone dependent reabsorption in more distal nephron segments. Thus, we suggest that the renal effects of rHuEPO may be part of a feedback system that serves to down-regulate the endogenous renal synthesis of EPO in the presence of high levels of circulating EPO. In support of such a feedback system, evidence exists to indicate that prolonged administration of rHuEPO results in a suppression of urinary excretion of endogenous EPO, and also the renal effects of rHuEPO fits well in the hypothesis advanced by Donnelly, arguing that the kidney operates as a 'critmeter' to regulate the EPO synthesis and body haematocrit through the metabolic signal of renal tissue oxygen pressure.

It has been suggested that the reduction in plasma volume induced by rHuEPO may be caused by the hyporeninemic hypoaldosteronism leading to natriuresis. In our previous study we did not perform actual sodium balance studies. However, the renal sodium loss necessary to account for the observed decrease in plasma volume is small, and it is possible that the net effect of rHuEPO was to cause a negative sodium balance during the entire 28 days treatment period.

Hypotheses

  1. rHuEPO decreases renal proximal tubular reabsorption, concentrations of renin and aldosterone, GFR, and overall renal perfusion.
  2. In subjects on a sodium-fixed diet, rHuEPO increases the sodium excretion causing a negative sodium balance.
  3. rHuEPO decreases renal oxygen consumption so as to augment oxygen tension at EPOproducing, interstitiel fibroblast-like cells in the juxtamedullary region.
  4. rHuEPO decreases renal synthesis and secretion of endogenous EPO.
  5. Blockade with specific endothelin antagonists (Bosantan) inhibits the renal effects of rHuEPO.

Research plan and methods The project includes normal subjects in which rHuEPO is administered according to previous protocols used by our group. In separate series subjects are given either 1) placebo, 2) rHuEPO (5,000 IU) every second day in two weeks, 3) rHuEPO (30,000 IU/day) for three days. Measurements are obtained at days 4, 11, 28. The trials are planned to be conducted in a double-blinded, cross-over design by which the subjects are randomised to three consecutive trial periods with either placebo, low-dose rHuEPO or high-dose rHuEPO separated by at least six weeks.

Study Type

Interventional

Enrollment (Actual)

16

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
    • Copenhagen East
      • Copenhagen, Copenhagen East, Denmark, 2100
        • Department of Clinical Physiology and Nuclear Medicine and PET, Rigshospitalet

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 38 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Male
  • Age between 20-40 years
  • Non smoker for min. a year
  • BP below 140/90
  • No medicine use
  • BMI below 25

Exclusion Criteria:

  • Participation in other medical trails
  • Allergi towards Erythropoietin
  • Malignity diseases
  • Epilepsy
  • Staying above 1500 meters within the last 3 months
  • Polycythemia
  • Elite athlete
  • Haematocrit above 55%

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
Drug: Placebo
1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
Active Comparator: Low dose Erythropoietin
Drug: Erythropoietin (Epoetin-beta, NeoRecormon®)
5000 IU/ml of NeoRecormon (Epoetin beta) is given subcutaneously as one ml before 10 O-clock a.m. on day 1,3,5,7,9,11 and 13. On day 1 and 3 5000 IU is given in one syringe and five ml of saline in total is given in five other syringes in order to maintain the double blinding. On day 2 six syringes of a total of 6 ml of saline is given in six syringes.
Drug: Erythropoietin (Epoetin-beta, NeoRecormon®)

30.000 IU of NeoRecormon (Epoetin beta) is given subcutaneously as a total of six ml (5.000 IU/ml) given in six syringes before 10 O-clock a.m. on day 1,2 and 3.

On day 5,7,9,11 and 13 six ml of saline in total is given in six syringes in order to maintain the double blinding.
Active Comparator: High dose Eryhropoietin
Drug: Erythropoietin (Epoetin-beta, NeoRecormon®)
5000 IU/ml of NeoRecormon (Epoetin beta) is given subcutaneously as one ml before 10 O-clock a.m. on day 1,3,5,7,9,11 and 13. On day 1 and 3 5000 IU is given in one syringe and five ml of saline in total is given in five other syringes in order to maintain the double blinding. On day 2 six syringes of a total of 6 ml of saline is given in six syringes.
Drug: Erythropoietin (Epoetin-beta, NeoRecormon®)

30.000 IU of NeoRecormon (Epoetin beta) is given subcutaneously as a total of six ml (5.000 IU/ml) given in six syringes before 10 O-clock a.m. on day 1,2 and 3.

On day 5,7,9,11 and 13 six ml of saline in total is given in six syringes in order to maintain the double blinding.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the Renal Blood Flow (RBF ml/min).
Time Frame: Day 4 and 25
Renal clearance studies with timed urine collections and renal venous catherization for measurements of renal perfusion (131I-Hippuran).
Day 4 and 25

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glomerular filtration rate (GFR ml/min)
Time Frame: Day 4, 11 and 25
Renal clearance studies with timed urine collections for measurements of GFR (51Cr-EDTA) and segmental renal handling of sodium and water (lithium clearance).
Day 4, 11 and 25
Segmental renal handling of sodium and water (lithium clearance).
Time Frame: Day 4, 11 and 25.
Renal clearance studies with timed urine collections and measurements of segmental renal handling of sodium and water (lithium clearance). All subjects will be studied during a sodiumfixed diet, with Lithiumcarbonat 300 mg given the evening before each studyday.
Day 4, 11 and 25.
Blood and plasma volume
Time Frame: Day 4, 11 and 25
With CO method blood and plasma volume are measured.
Day 4, 11 and 25
Analysis of hormones and proteins.
Time Frame: Day 4, 11 and 25.
Analysis of concentrations of rHuEPO, EPO, renin, aldosterone, endothelin-1, nitrite/nitrate, citrulline, sodium and asymmetric dimethylarginine in urine, renal venous blood and venous blood.
Day 4, 11 and 25.
Endothel function
Time Frame: Day 4, 11 and 25
Endothel function measured with non-invasive arteriel tonometri (Endopat 2000).
Day 4, 11 and 25

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Copenhagen

Collaborators

Rigshospitalet, Denmark

Investigators

  • Study Chair: Niels Vidiendal Olsen, M.D., D.M.Sc., Department of Neuroscience and Pharmacology, University of Copenhagen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2012

Primary Completion (Actual)

August 1, 2013

Study Completion (Actual)

September 1, 2013

Study Registration Dates

First Submitted

April 24, 2012

First Submitted That Met QC Criteria

April 24, 2012

First Posted (Estimate)

April 25, 2012

Study Record Updates

Last Update Posted (Estimate)

November 5, 2013

Last Update Submitted That Met QC Criteria

November 4, 2013

Last Verified

November 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • H-2-2011-068

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Renal Effects

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe